Ionis Pharma (IONS): Data Presentations Increase Confidence - BMO

October 10, 2016 9:58 AM EDT
Get Alerts IONS Hot Sheet
Price: $45.92 -1.37%

Rating Summary:
    2 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade IONS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst, Do Kim, reiterated his Outperform rating on shares of Ionis Pharmaceuticals (NASDAQ: IONS) after Ionis and Avexis had key data presentations at the 2016 World Muscle Society (MWS), where both Nusinersen and AVX-101 showed impressive diseasealtering improvements in a previously untreatable disorder.

The analyst believes Nusinersen's Phase II NURTURE study in pre-symptomatic patients supports nearly normal development (no events) of type 1 patients, similar to Avexis's Phase I data. The analyst believes NURTURE could bridge any efficacy difference seen between the two drugs. Upcoming key catalysts will be AXVS-101 Phase III study design and Nusinersen's approval timing. No change to the price target of $48.

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $34.26 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

BMO Capital, S1

Add Your Comment